Standard Chem & Pharm Co Ltd
TWSE:1720
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
TW |
|
Thinking Electronic Industrial Co Ltd
TWSE:2428
|
TW |
Multiples-Based Value
The
Multiples-Based Value for
Standard Chem & Pharm Co Ltd (1720)
under the Base Case is
73.1
TWD.
Compared with the current market price of 63.5 TWD, the stock appears
Undervalued by 13%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
Standard Chem & Pharm Co Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| TW |
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
11.3B TWD | 1.6 | 12.2 | 5.5 | 7.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.4 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
229B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GSK plc
XETRA:GS71
|
99.8B EUR | 2.7 | 15.2 | 8.2 | 10.2 |